An exploratory study of nimotuzumab combined with toripalimab and chemotherapy for locally advanced tonsillar cancer.
Jingxuan Shi, Zhaoxiang Wang, Qianqian Zhao...
https://pubmed.ncbi.nlm.nih.gov/42523785/Actively Recruiting
Led by Tang-Du Hospital · Updated on 2026-01-20
10
Participants Needed
1
Research Sites
263 weeks
Total Duration
Researchers are evaluating the effectiveness and safety of combining nimotuzumab, toripalimab, and chemotherapy to treat patients with locally advanced tonsillar cancer. This prospective, single-arm Phase II study aims to see if this combination can improve the pathological complete response rate and overall survival compared to historical data. Approximately 10 patients will be enrolled with a follow-up period extending up to five years after enrollment to monitor long-term outcomes. Participants receive nimotuzumab 400 mg, toripalimab 240 mg, nab-paclitaxel 260 mgm, and carboplatin through intravenous infusions every three weeks for 2 to 4 cycles. Each infusion lasts at least 60 minutes with careful monitoring for reactions. After 2 to 4 cycles of this neoadjuvant combination therapy, patients undergo endoscopy and imaging evaluation around day 42 to assess response. Throughout the study, participants will have assessments including pathological examination within 1 to 2 weeks after radical surgery to measure the pathological complete response rate, surgical margins, and major pathological response. Radiological response rates are evaluated after completing two treatment cycles, and functional status is assessed before surgery and at 1 month, 6 months, and 1 year post-surgery or concurrent chemoradiotherapy. Disease-free survival will be followed for up to 72 months. Participants must comply with study procedures and follow-up visits during this period.
CONDITIONS
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
Z
Zhao DaQing
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tang-Du Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Screening and enrollment visit
Duration - 6 to 12 weeks
Participants receive neoadjuvant treatment with Nimotuzumab, Toripalimab, Nab-paclitaxel, and Carboplatin administered intravenously every 3 weeks for 2 to 4 cycles.
2 to 4 infusion visits every 3 weeks
Duration - Approximately 3 weeks
After completion of 2 cycles of neoadjuvant treatment, participants undergo endoscopy combined with imaging evaluation followed by radical surgery performed 2 to 3 weeks later.
1 surgery visit and 1 imaging/endoscopy visit
Duration - Up to 5 years
Participants are followed for functional preservation assessments and disease-free survival monitoring for up to 5 years after treatment initiation.
Visits at 1 month, 6 months, 1 year, and periodic visits up to 5 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Jingxuan Shi, Zhaoxiang Wang, Qianqian Zhao...
https://pubmed.ncbi.nlm.nih.gov/42523785/Tang-Du Hospital
Lead Sponsor